Market revenue in 2023 | USD 378.7 million |
Market revenue in 2030 | USD 853.6 million |
Growth rate | 12.3% (CAGR from 2023 to 2030) |
Largest segment | Functional genomics |
Fastest growing segment | Pathway Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genomics market will help companies and investors design strategic landscapes.
Functional genomics was the largest segment with a revenue share of 32.35% in 2023. Horizon Databook has segmented the Mexico genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico, being a developing economy, witnessed several challenges in implementing novel genomic technologies in healthcare. These challenges include inadequate nutrition, limited resources, and lack of robust research network.
To address these concerns, several initiatives have been taken in the country that focus on detailed study of genetic makeup. Notably, in 2020, the primary causes of mortality in Mexico are cardiac conditions with almost 172,000 deaths, followed by deaths due to diabetes and stroke.
Substantial initiatives are being undertaken by government and corporate organizations in Mexico to boost genomics market growth. For instance, genomic medicine research in Mexico is led by the National Institute of Genomic Medicine (INMEGEN), established as the 11th NIH and a promoter consortium of the Institute of Genomic Medicine in Mexico.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico genomics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico genomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account